{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T23:55:14Z","timestamp":1795046114633,"version":"4.10.2"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The University of Osaka"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Claudin-18 isoform-2 (CLDN18.2) is a novel biomarker and therapeutic target for gastric cancer (GC). It may exhibit the intratumoral heterogeneity and varying expressions between biopsy and surgically resected specimens as well as pre- and post-chemotherapy, which could impact patient selection for the targeted agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>CLDN18.2 expression was immunohistochemically evaluated in pretreatment biopsy and surgically resected specimens from 183 patients with pT2-T4 GC who underwent upfront gastrectomy. The intratumoral heterogeneity was evaluated by classifying the distribution of CLDN18.2 positive cells as superficial, invasive-front, or random pattern. Furthermore, a separate cohort of 38 patients who underwent neoadjuvant chemotherapy without zolbetuximab were analyzed to compare the pre- and post-treatment CLDN18.2 status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>CLDN18.2 positivity was observed in 31% (56\/183) of patients. Among the 93 patients with 2\u2009+\u2009\/3\u2009+\u2009expression in\u2009\u2265\u200910% of the tumor cells, 81 (87%) had heterogeneous expression patterns, including superficial (n\u2009=\u200946), random (n\u2009=\u200924), and invasive-front (n\u2009=\u200911) patterns. The overall biopsy\u2013surgery concordance rate was 86% (157\/183), but it decreased to 73% (59\/81) in patients with a heterogeneous expression pattern. Notably, the concordance rate was particularly low in the superficial pattern, at only 65% (30\/46). Among the 38 patients who underwent neoadjuvant chemotherapy, only 4 of 11 initially CLDN18.2-positive cases remained positive after treatment, although the overall concordance rate was 82% (31\/38).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The CLDN18.2 expression demonstrated an acceptable concordance between biopsy and surgically resected specimens. However, high prevalence of heterogeneous expression and tendency for CLDN18.2 positivity to shift to negativity following chemotherapy existed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10147-026-02972-w","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T14:02:26Z","timestamp":1769608946000},"page":"621-629","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Intratumoral heterogeneity and chemotherapy-induced alteration of CLDN18.2 expression in resectable gastric cancer"],"prefix":"10.1007","volume":"31","author":[{"given":"Shinnosuke","family":"Nagano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2883-0132","authenticated-orcid":false,"given":"Yukinori","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaomi","family":"Hagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Motoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Momose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Makino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyokazu","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Morii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"2972_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263","journal-title":"CA Cancer J Clin"},{"key":"2972_CR2","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/ags3.12717","volume":"7","author":"M Tokunaga","year":"2023","unstructured":"Tokunaga M, Kurokawa Y, Fukagawa T et al (2023) Neoadjuvant chemotherapy for locally advanced gastric cancer in Japan: consensus meeting at the 77th general meeting of the Japanese Society of Gastroenterological Surgery. Ann Gastroenterol Surg 7:856\u2013862","journal-title":"Ann Gastroenterol Surg"},{"key":"2972_CR3","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1002\/ags3.12835","volume":"8","author":"T Higashi","year":"2024","unstructured":"Higashi T, Kurokawa Y (2024) Incidence, mortality, survival, and treatment statistics of cancers in digestive organs-Japanese cancer statistics 2024. Ann Gastroenterol Surg 8:958\u2013965","journal-title":"Ann Gastroenterol Surg"},{"key":"2972_CR4","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S2468-1253(18)30090-6","volume":"3","author":"Y Kurokawa","year":"2018","unstructured":"Kurokawa Y, Doki Y, Mizusawa J et al (2018) Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol 3:460\u2013468","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2972_CR5","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/ags3.12711","volume":"7","author":"Y Yanagimoto","year":"2023","unstructured":"Yanagimoto Y, Kurokawa Y, Doki Y (2023) Essential updates 2021\/2022: perioperative and surgical treatments for gastric and esophagogastric junction cancer. Ann Gastroenterol Surg 7:698\u2013708","journal-title":"Ann Gastroenterol Surg"},{"key":"2972_CR6","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.celrep.2015.06.020","volume":"12","author":"F Yao","year":"2015","unstructured":"Yao F, Kausalya JP, Sia YY et al (2015) Recurrent Fusion Genes in Gastric Cancer: CLDN18-ARHGAP26 Induces Loss of Epithelial Integrity. Cell Rep 12:272\u2013285","journal-title":"Cell Rep"},{"key":"2972_CR7","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin U, Koslowski M, Dhaene K et al (2008) Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res 14:7624\u20137634","journal-title":"Clin Cancer Res"},{"key":"2972_CR8","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00543","volume":"8","author":"R Waters","year":"2024","unstructured":"Waters R, Sewastjanow-Silva M, Yamashita K et al (2024) Retrospective study of claudin 18 isoform 2 prevalence and prognostic association in gastric and gastroesophageal junction adenocarcinoma. JCO Precis Oncol 8:e2300543","journal-title":"JCO Precis Oncol"},{"key":"2972_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02421-1","volume":"20","author":"K Jia","year":"2022","unstructured":"Jia K, Chen Y, Sun Y et al (2022) Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer. BMC Med 20:223","journal-title":"BMC Med"},{"key":"2972_CR10","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA et al (2023) Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med 29:2133\u20132141","journal-title":"Nat Med"},{"key":"2972_CR11","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang Y-J et al (2023) Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 401:1655\u20131668","journal-title":"Lancet"},{"key":"2972_CR12","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s10120-014-0430-7","volume":"18","author":"Y Kurokawa","year":"2015","unstructured":"Kurokawa Y, Matsuura N, Kimura Y et al (2015) Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer. Gastric Cancer 18:691\u2013697","journal-title":"Gastric Cancer"},{"key":"2972_CR13","doi-asserted-by":"publisher","first-page":"5879","DOI":"10.3748\/wjg.v22.i26.5879","volume":"22","author":"F Grillo","year":"2016","unstructured":"Grillo F, Fassan M, Sarocchi F et al (2016) HER2 heterogeneity in gastric\/gastroesophageal cancers: From benchside to practice. World J Gastroenterol 22:5879\u20135887","journal-title":"World J Gastroenterol"},{"key":"2972_CR14","doi-asserted-by":"publisher","first-page":"7381","DOI":"10.1158\/1078-0432.CCR-09-1735","volume":"15","author":"EA Mittendorf","year":"2009","unstructured":"Mittendorf EA, Wu Y, Scaltriti M et al (2009) Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 15:7381\u20137388","journal-title":"Clin Cancer Res"},{"key":"2972_CR15","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.21873\/invivo.11405","volume":"32","author":"S Shu","year":"2018","unstructured":"Shu S, Iimori M, Nakanishi R et al (2018) Changes in HER2 expression and amplification status following preoperative chemotherapy for gastric cancer. In Vivo 32:1491\u20131498","journal-title":"In Vivo"},{"key":"2972_CR16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.21873\/anticanres.13927","volume":"40","author":"T Kijima","year":"2020","unstructured":"Kijima T, Arigami T, Uenosono Y et al (2020) Comparison of HER2 status before and after trastuzumab-based chemotherapy in patients with advanced gastric cancer. Anticancer Res 40:75\u201380","journal-title":"Anticancer Res"},{"key":"2972_CR17","unstructured":"(2017) Japanese Classification Gastric Carcinoma. Kanehara Shuppan, Tokyo"},{"key":"2972_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-68411-w","volume":"14","author":"E Choi","year":"2024","unstructured":"Choi E, Shin J, Ryu M-H et al (2024) Heterogeneity of claudin 18.2 expression in metastatic gastric cancer. Sci Rep 14:17648","journal-title":"Sci Rep"},{"key":"2972_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-47178-6","volume":"13","author":"H-D Kim","year":"2023","unstructured":"Kim H-D, Choi E, Shin J et al (2023) Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer. Sci Rep 13:20047","journal-title":"Sci Rep"},{"key":"2972_CR20","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1007\/s10120-024-01505-6","volume":"27","author":"H Ogawa","year":"2024","unstructured":"Ogawa H, Abe H, Yagi K et al (2024) Claudin-18 status and its correlation with HER2 and PD-L1 expression in gastric cancer with peritoneal dissemination. Gastric Cancer 27:802\u2013810","journal-title":"Gastric Cancer"},{"key":"2972_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155145","volume":"254","author":"V Angerilli","year":"2024","unstructured":"Angerilli V, Ghelardi F, Nappo F et al (2024) Claudin-18.2 testing and its impact in the therapeutic management of patients with gastric and gastroesophageal adenocarcinomas: a literature review with expert opinion. Pathol Res Pract 254:155145","journal-title":"Pathol Res Pract"},{"key":"2972_CR22","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1007\/s10120-024-01518-1","volume":"27","author":"K Shitara","year":"2024","unstructured":"Shitara K, Xu R-H, Ajani JA et al (2024) Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Gastric Cancer 27:1058\u20131068","journal-title":"Gastric Cancer"},{"key":"2972_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11111095","author":"A Pellino","year":"2021","unstructured":"Pellino A, Brignola S, Riello E et al (2021) Association of CLDN18 protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction adenocarcinomas. J Pers Med. https:\/\/doi.org\/10.3390\/jpm11111095","journal-title":"J Pers Med"},{"issue":"1","key":"2972_CR24","doi-asserted-by":"publisher","first-page":"100762","DOI":"10.1016\/j.esmoop.2022.100762","volume":"8","author":"Y Kubota","year":"2023","unstructured":"Kubota Y, Kawazoe A, Mishima S et al (2023) Comprehensive clinical and molecular characterization of claudin 18. 2 expression in advanced gastric or gastroesophageal junction cancer. ESMO Open 8(1):100762","journal-title":"ESMO Open"},{"key":"2972_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104000","volume":"9","author":"T-Y Kim","year":"2024","unstructured":"Kim T-Y, Kwak Y, Nam SK et al (2024) Clinicopathological analysis of claudin 18.2 focusing on intratumoral heterogeneity and survival in patients with metastatic or unresectable gastric cancer. ESMO Open 9:104000","journal-title":"ESMO Open"},{"key":"2972_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmogo.2024.100086","volume":"5","author":"U Okazaki","year":"2024","unstructured":"Okazaki U, Nakayama I, Sakamoto N et al (2024) Clinical implementation of simultaneous multiple biomarkers testing for metastatic or recurrent gastroesophageal adenocarcinoma: a single-institutional experience. ESMO Gastrointestinal Oncology 5:100086","journal-title":"ESMO Gastrointestinal Oncology"},{"key":"2972_CR27","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1007\/s12094-020-02380-0","volume":"22","author":"A Arnold","year":"2020","unstructured":"Arnold A, Daum S, von Winterfeld M et al (2020) Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas. Clin Transl Oncol 22:2357\u20132363","journal-title":"Clin Transl Oncol"},{"key":"2972_CR28","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41416-019-0508-4","volume":"121","author":"I Coati","year":"2019","unstructured":"Coati I, Lotz G, Fanelli GN et al (2019) Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases. Br J Cancer 121:257\u2013263","journal-title":"Br J Cancer"},{"key":"2972_CR29","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/j.1349-7006.2007.00490.x","volume":"98","author":"Y Matsuda","year":"2007","unstructured":"Matsuda Y, Semba S, Ueda J et al (2007) Gastric and intestinal claudin expression at the invasive front of gastric carcinoma. Cancer Sci 98:1014\u20131019","journal-title":"Cancer Sci"},{"key":"2972_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074757","volume":"8","author":"T Oshima","year":"2013","unstructured":"Oshima T, Shan J, Okugawa T et al (2013) Down-regulation of claudin-18 is associated with the proliferative and invasive potential of gastric cancer at the invasive front. PLoS ONE 8:e74757","journal-title":"PLoS ONE"},{"key":"2972_CR31","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1159\/000101049","volume":"74","author":"J Ueda","year":"2007","unstructured":"Ueda J, Semba S, Chiba H et al (2007) Heterogeneous expression of claudin-4 in human colorectal cancer: decreased claudin-4 expression at the invasive front correlates cancer invasion and metastasis. Pathobiology 74:32\u201341","journal-title":"Pathobiology"},{"key":"2972_CR32","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.humpath.2005.12.018","volume":"37","author":"Y Usami","year":"2006","unstructured":"Usami Y, Chiba H, Nakayama F et al (2006) Reduced expression of claudin-7 correlates with invasion and metastasis in squamous cell carcinoma of the esophagus. Hum Pathol 37:569\u2013577","journal-title":"Hum Pathol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-02972-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-02972-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-02972-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:12:55Z","timestamp":1774415575000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-02972-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2972"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-02972-w","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"25 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.N. and Y.K. received lecture fees from Astellas Pharma outside of the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (The University of Osaka Hospital Ethical Review Board, No. 8226\u201310,\u00a024425) and with the Helsinki Declaration of 1964 and later versions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}